Chimeric Therapeutics Limited (CHM.AX)
AUD 0.01
(-14.29%)
AUD 0.01
(-14.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -11.29 Million AUD | 52.95% |
| 2023 | -24.01 Million AUD | -121.65% |
| 2022 | -13.62 Million AUD | 14.81% |
| 2021 | -13.99 Million AUD | -23498.19% |
| 2020 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -6.77 Million AUD | -155.31% |
| 2024 FY | - AUD | 27.37% |
| 2024 Q2 | -8.72 Million AUD | -336.41% |
| 2024 Q1 | 1.12 Million AUD | 107.57% |
| 2024 Q4 | -16.77 Million AUD | -82.04% |
| 2023 Q1 | -5.58 Million AUD | -145.36% |
| 2023 Q2 | -5.58 Million AUD | 0.0% |
| 2023 Q4 | -6.42 Million AUD | 0.0% |
| 2023 Q3 | -6.42 Million AUD | -15.01% |
| 2023 FY | - AUD | -121.65% |
| 2022 Q4 | -2.27 Million AUD | 0.0% |
| 2022 Q3 | -2.27 Million AUD | 49.81% |
| 2022 Q2 | -4.53 Million AUD | 0.0% |
| 2022 Q1 | -4.53 Million AUD | 16.17% |
| 2022 FY | - AUD | 14.81% |
| 2021 Q4 | -5.41 Million AUD | -3951.87% |
| 2021 FY | - AUD | -23498.19% |
| 2021 Q3 | -133.52 Thousand AUD | -1483666.67% |
| 2021 Q1 | 10.00 AUD | 0.0% |
| 2021 Q2 | 9.00 AUD | -10.0% |
| 2020 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 208.909% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -675.73% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 68.992% |
| Biome Australia Limited | -1.57 Million AUD | -615.969% |
| Patrys Limited | -3.49 Million AUD | -223.576% |
| Orthocell Limited | -11.68 Million AUD | 3.265% |
| Imugene Limited | -147.97 Million AUD | 92.364% |
| Noxopharm Limited | -5.94 Million AUD | -90.056% |
| PYC Therapeutics Limited | -38.11 Million AUD | 70.355% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -57.254% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -43.265% |
| Cynata Therapeutics Limited | -9.95 Million AUD | -13.563% |
| CSL Limited | 4.73 Billion AUD | 100.239% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -27.925% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -279.826% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 121.788% |
| Starpharma Holdings Limited | -12.57 Million AUD | 10.155% |
| Nanollose Limited | -1.14 Million AUD | -884.386% |
| Memphasys Limited | -3.3 Million AUD | -241.618% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -1468.453% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -529.064% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -147.824% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 18.82% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -300.969% |
| Race Oncology Limited | -14.2 Million AUD | 20.443% |
| Nyrada Inc. | -4.59 Million AUD | -145.85% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 149.202% |
| Dimerix Limited | -24.95 Million AUD | 54.726% |
| PharmAust Limited | -9.45 Million AUD | -19.553% |
| Immutep Limited | -42.87 Million AUD | 73.645% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 74.691% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 42.264% |
| BTC Health Limited | 1.05 Million AUD | 1170.778% |
| Acrux Limited | -7.93 Million AUD | -42.476% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 105.671% |
| Biotron Limited | -5.04 Million AUD | -124.2% |
| Tissue Repair Ltd | -5.77 Million AUD | -95.667% |
| AdAlta Limited | -5.3 Million AUD | -113.095% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 75.098% |
| Hexima Limited | -995.54 Thousand AUD | -1035.037% |
| AnteoTech Limited | -11.57 Million AUD | 2.344% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 82.492% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 47.084% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -248.489% |
| Actinogen Medical Limited | -12.92 Million AUD | 12.548% |
| Immuron Limited | -6.19 Million AUD | -82.479% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -495.48% |